What is Zacks Research’s Estimate for Hologic Q1 Earnings?

Hologic, Inc. (NASDAQ:HOLX) – Equities research analysts at Zacks Research increased their Q1 2026 earnings per share estimates for shares of Hologic in a note issued to investors on Monday, November 24th. Zacks Research analyst Team now expects that the medical equipment provider will earn $1.07 per share for the quarter, up from their prior estimate of $1.06. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic’s Q2 2026 earnings at $1.08 EPS, FY2026 earnings at $4.45 EPS, Q1 2027 earnings at $1.20 EPS, Q2 2027 earnings at $1.26 EPS, FY2027 earnings at $4.92 EPS and FY2028 earnings at $5.35 EPS.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.03 billion. During the same quarter last year, the company earned $1.01 earnings per share. Hologic’s quarterly revenue was up 6.2% compared to the same quarter last year.

HOLX has been the subject of a number of other research reports. Leerink Partners raised their price target on Hologic from $70.00 to $78.00 and gave the company a “market perform” rating in a research report on Tuesday, October 21st. Stephens cut shares of Hologic from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $78.00 to $76.00 in a research report on Wednesday, October 22nd. Wall Street Zen lowered shares of Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Raymond James Financial cut shares of Hologic from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. Finally, Morgan Stanley lifted their price objective on Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Five research analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $79.67.

Hologic Stock Down 0.1%

Shares of NASDAQ HOLX opened at $74.80 on Wednesday. The firm has a 50-day moving average price of $71.30 and a 200 day moving average price of $66.84. The stock has a market capitalization of $16.67 billion, a price-to-earnings ratio of 31.04, a price-to-earnings-growth ratio of 2.54 and a beta of 0.65. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. Hologic has a 52 week low of $51.90 and a 52 week high of $80.31.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. NewEdge Wealth LLC increased its stake in Hologic by 3.8% during the third quarter. NewEdge Wealth LLC now owns 3,779 shares of the medical equipment provider’s stock worth $281,000 after acquiring an additional 138 shares during the last quarter. Capital Investment Counsel Inc increased its position in Hologic by 2.6% during the 2nd quarter. Capital Investment Counsel Inc now owns 5,814 shares of the medical equipment provider’s stock worth $379,000 after purchasing an additional 150 shares in the last quarter. Savant Capital LLC raised its holdings in Hologic by 0.9% in the third quarter. Savant Capital LLC now owns 19,776 shares of the medical equipment provider’s stock valued at $1,335,000 after buying an additional 170 shares during the period. Greenleaf Trust lifted its position in Hologic by 5.1% during the second quarter. Greenleaf Trust now owns 3,579 shares of the medical equipment provider’s stock valued at $233,000 after buying an additional 173 shares in the last quarter. Finally, UMB Bank n.a. grew its stake in Hologic by 38.7% during the third quarter. UMB Bank n.a. now owns 620 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 173 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Christiana Stamoulis sold 7,402 shares of the company’s stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $73.07, for a total transaction of $540,864.14. Following the completion of the transaction, the director owned 47,336 shares of the company’s stock, valued at approximately $3,458,841.52. This represents a 13.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the transaction, the chief executive officer owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 1.88% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.